- Record: found
- Abstract: found
- Article: not found
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Marco Cicardi
1 ,
Aleena Banerji ,
Francisco Bracho ,
Alejandro Malbrán ,
Bernd Rosenkranz ,
Marc Riedl ,
Konrad Bork ,
William Lumry ,
Werner Aberer ,
Henning Bier ,
Murat Bas ,
Jens Greve ,
Thomas K Hoffmann ,
Henriette Farkas ,
Avner Reshef ,
Bruce Ritchie ,
William Yang ,
Jürgen Grabbe ,
Shmuel Kivity ,
Wolfhart Kreuz ,
Robyn J Levy ,
Thomas Luger ,
Krystyna Obtulowicz ,
Peter Schmid-Grendelmeier ,
Christian Bull ,
Brigita Sitkauskiene ,
William B Smith ,
Elias Toubi ,
Sonja Werner ,
Suresh Anné ,
Janne Björkander ,
Laurence Bouillet ,
Enrico Cillari ,
David Hurewitz ,
Kraig W Jacobson ,
Constance H Katelaris ,
Marcus Maurer ,
Hans Merk ,
Jonathan A Bernstein ,
Conleth Feighery ,
Bernard Floccard ,
Gerald Gleich ,
Jacques Hébert ,
Martin Kaatz ,
Paul Keith ,
Charles H Kirkpatrick ,
David Langton ,
Ludovic Martin ,
Christiane Pichler ,
David Resnick ,
Duane Wombolt ,
Diego S Fernández Romero ,
Andrea Zanichelli ,
Francesco Arcoleo ,
Jochen Knolle ,
Irina Kravec ,
Liying Dong ,
Jens Zimmermann ,
Kimberly Rosen ,
Wing-Tze Fan
Aug 05 2010
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Hereditary angioedema is characterized by recurrent attacks of angioedema of the skin, larynx, and gastrointestinal tract. Bradykinin is the key mediator of symptoms. Icatibant is a selective bradykinin B2 receptor antagonist.